10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who have difficulty swallowing medication.
Takeda Canada announced today that Health Canada has authorized a chewable tablet of Vyvanse (lisdexamfetamine dimesylate). This is the first and only chewable treatment for patients with attention deficit/hyperactivity disorder aged six and older.
Vyvanse chewable tablets are also indicated for the treatment of moderate to severe binge eating disorder in adults aged 18 and older.